Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of camrelizumab combined with rituximab, vincristine,
doxorubicin, cyclophosphamide and prednisone in the treatment of untreated primary extranodal
DLBCL